Commentary|Podcasts|November 4, 2025

Streamlining Clinical Data to Reduce Site and Participant Burden

In this episode of the ACT Podcast, Jeneen Donadeo, executive director of portfolio management at TransCelerate, and Laura Galuchie, senior director and TransCelerate program lead at Merck, discuss the findings from a recent TransCelerate and Tufts CSDD study revealing that nearly one-third of data collected in Phase III trials is non-essential. They explore why trial complexity continues to grow despite industry efforts toward efficiency and share strategies for reducing data burden while maintaining compliance.

Jeneen Donadeo, executive director of portfolio management at TransCelerate, and Laura Galuchie, senior director and TransCelerate program lead at Merck, discuss:

Why clinical trial protocols continue to grow more complex despite efficiency initiatives
Practical steps to streamline data collection while meeting regulatory expectations
How sponsors, CROs, and sites can better collaborate on smarter data strategies to reduce burden and improve trial outcomes
And more!

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!